關(guān)鍵詞： 羅氏 Illumina
2012年12月21日訊 /生物谷BIOON/ --在瑞士報(bào)紙L'Agefi報(bào)道羅氏有可能再次收購Illumina之后,，Illumina股票本周四大漲7%,，羅氏股票價格略有小跌,。
L'Agefi聲稱,，這一消息可靠但是還未得到證實(shí),，這份報(bào)紙聲稱兩家公司在上周達(dá)成以每股66美元的價格收購意向,，這使交易價格將達(dá)到81億美元到82億美元間,。
今年四月份,，Illumina拒絕了羅氏的67億美元的收購要約,，羅氏最終于4月20日停止了對Illumina的收購計(jì)劃。
羅氏發(fā)言人對此尚未置評，分析家們對此表示懷疑,。（生物谷Bioon.com）
“劇情”回顧
羅氏愿意進(jìn)行30億美元規(guī)模并購交易
羅氏向Illumina發(fā)出敵意收購要約報(bào)價57億美元
Illumina推出毒丸計(jì)劃回應(yīng)羅氏
Illumina拒絕羅氏57億美元收購要約
羅氏做好打持久戰(zhàn)的準(zhǔn)備
羅氏延長對Illumina收購要約
羅氏施壓Illumina稱收購失敗還有其他選項(xiàng)
Illumina再拒羅氏敵意收購
羅氏再次延長對Illumina敵意收購報(bào)價截止期限
羅氏上調(diào)收購Illumina報(bào)價至65億美元
Illumina公司拒絕羅氏67億美元收購要約
Illumina自比蘋果 羅氏有意再度上調(diào)收購價格
羅氏發(fā)表聲明—不延長對Illumina公司的收購要約
英文報(bào)道：
Shares in Illumina (ILMN.O) jumped 7 percent on Thursday, after Swiss newspaper L'Agefi reported that Roche may have reached an agreement to buy the U.S. gene-sequencing company.
Citing "information that appears trustworthy but could not be verified", the paper said the two parties may have last week agreed on a transaction price of $66 per share which would value the company between $8.1 billion and $8.2 billion.
The paper added that nothing was finalized yet, but that an announcement could come in the first half of January.
Roche spokesman Alexander Klauser said the company did not comment on market rumors.
Roche walked away from a $6.8 billion bid for Illumina in April after shareholders blocked its move to gain seats on the U.S. firm's board. Severin Schwan had earlier ridiculed Illumina's claim to be "the Apple of the genomics business".
Analysts were skeptical about the report.
"The price tag looks quite high as it would represents a premium of 48 percent versus the initial offer a year ago," said Helvea analyst Odile Rundquist. "For a company having revenues of roughly $1 billion, that values the deal at eight times sales."
By 10 a.m. ET shares in Illumina were trading up 7 percent at $55.90. Shares in Roche (ROG.VX) were down 1.3 percent at 184.6 Swiss francs.
